臨床泌尿器科78巻7号

2024年06月発行

特集 キャッチアップ精巣腫瘍―今，知っておくべき進歩

〈トピックス〉

予後良好な進行性セミノーマの化学療法

著者： 河野勤¹

所属機関： ¹佐々木研究所附属杏雲堂病院 腫瘍内科

ページ範囲：P.488 - P.492

文献概要

▶ポイント

・予後良好群進行性セミノーマにおける標準的化学療法は，BEP療法3コースあるいはEP療法4コースである．

・予後良好群の予後は，IGCCCGのアップデート解析によると，5年無増悪生存割合が89％にまで改善している．

・効果を維持しながら毒性をさらに軽減する治療法（de-escalation）の研究が進行している．

参考文献

1） Hanna NH, et al : Testicular Cancer ― Discoveries and Updates. N Engl J Med 371 : 2005-2016, 2014

2） Williams SD, et al : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 : 1435-1440, 1987

3） Bajorin DF, et al : Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors : a multiinstitutional study. J Clin Oncol 11 : 598-606, 1993

4） Sr Loehrer PJ, et al : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors : an Eastern Cooperative Oncology Group trial. J Clin Oncol 13 : 470-476, 1995

5） de Wit R, et al : Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19 : 1629-1640, 2001

6） Horwich A, et al : Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer : a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15 : 1844-1852, 1997

7） de Wit R, et al : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15 : 1837-1843, 1997

8） Culine S, et al : Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers （GETUG T93BP）. Ann Oncol 18 : 917-924, 2007

9） Patrikidou A, et al : European Association of Urology Guidelines on Testicular Cancer : 2023 Update. Eur Urol 84 : 289-301, 2023

10） International Germ Cell Consensus Classification : a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15 : 594-603, 1997

11） Beyer J, et al : Survival and New Prognosticators in Metastatic Seminoma : Results From the IGCCCG-Update Consortium. J Clin Oncol 39 : 1553-1562, 2021

12） Fizazi K, et al : A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma : Results of the GETUG S99 Multicenter Prospective Study. Eur Urol 65 : 381-386, 2014

13） Krege S, et al : Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group （GTCSG）. Ann Oncol 17 : 276-280, 2006

14） Bokemeyer C, et al : Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy : a pooled analysis of two randomised trials. Br J Cancer 91 : 683-687, 2004

15） Alifrangis C, et al : Single-agent carboplatin AUC10 in metastatic seminoma : A multi-centre UK study of 216 patients. Eur J Cancer 164 : 105-113, 2022

16） Loriot Y, et al : The GETUG SEMITEP Trial : De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Eur Urol 82 : 172-179, 2022